Clinical Trial Update: Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tremelimumab and durvalumab, alone or in combination, for recurrent malignant glioma including recurrent glioblastoma; completed with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Malignant Glioma

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Northwestern University | Conditions: Malignant Glioma, Recurrent Glioblastoma | Phase 2 | Status: COMPLETED | Results posted: 2022-04-18